Apellis Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 78.33
| APLS Stock | USD 28.00 0.08 0.29% |
Apellis |
Apellis Pharmaceuticals Target Price Odds to finish over 78.33
The tendency of Apellis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 78.33 or more in 90 days |
| 28.00 | 90 days | 78.33 | near 1 |
Based on a normal probability distribution, the odds of Apellis Pharmaceuticals to move over $ 78.33 or more in 90 days from now is near 1 (This Apellis Pharmaceuticals probability density function shows the probability of Apellis Stock to fall within a particular range of prices over 90 days) . Probability of Apellis Pharmaceuticals price to stay between its current price of $ 28.00 and $ 78.33 at the end of the 90-day period is more than 93.0 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.5 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Apellis Pharmaceuticals will likely underperform. Additionally Apellis Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Apellis Pharmaceuticals Price Density |
| Price |
Predictive Modules for Apellis Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Apellis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Apellis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Apellis Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Apellis Pharmaceuticals is not an exception. The market had few large corrections towards the Apellis Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Apellis Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Apellis Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.54 | |
β | Beta against Dow Jones | 1.50 | |
σ | Overall volatility | 4.63 | |
Ir | Information ratio | -0.15 |
Apellis Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Apellis Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Apellis Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Apellis Announces Oral Presentation at American Society of Nephrology Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN |
Apellis Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Apellis Stock often depends not only on the future outlook of the current and potential Apellis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Apellis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 118.7 M | |
| Cash And Short Term Investments | 352.3 M |
Apellis Pharmaceuticals Technical Analysis
Apellis Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Apellis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Apellis Pharmaceuticals. In general, you should focus on analyzing Apellis Stock price patterns and their correlations with different microeconomic environments and drivers.
Apellis Pharmaceuticals Predictive Forecast Models
Apellis Pharmaceuticals' time-series forecasting models is one of many Apellis Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Apellis Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Apellis Pharmaceuticals
Checking the ongoing alerts about Apellis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Apellis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Apellis Announces Oral Presentation at American Society of Nephrology Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.